MWNA
RARX

Marshall Wace North America’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Marshall Wace North America’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,080
Closed -$256K – 1724
2017
Q3 		$256K Buy
+17,080
New +$258K ﹤0.01% 1154

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Marshall Wace North America's RARX Position: Q4 2017 in Review

Marshall Wace North America sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2017, closing a stake of 17,080 shares — an estimated $256K sold.

Marshall Wace North America first reported a position in RARX in Q3 2017 and held it in 1 quarter. The position peaked at $256K in Q3 2017. 66 funds tracked by Wall St. Rank hold RARX as of Q4 2017.

  • Marshall Wace North America reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 17,080 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $256K.
  • Marshall Wace North America first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Marshall Wace North America's Ra Pharmaceuticals, Inc. Common Stock position peaked at $256K in Q3 2017.
  • 66 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.